Mode
Text Size
Log in / Sign up
N/A N=31 Randomized Treatment

Effect of Inpatient Diabetes Management on Outpatient Glycemic Control

Diabetes Mellitus, Type 2

Enrolled (actual)
31
Serious AEs
6.5%
Results posted
Nov 2012
Primary outcome: Primary: Hemoglobin A1c — -1.3; -0.4 HbA1c, %

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Diabetes management team (Other)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Massachusetts General Hospital
Primary completion
Jul 2011

Outcome Measures

OutcomeResultp-value
PRIMARY
Hemoglobin A1c
-1.3; -0.4
SECONDARY
Average Intervention Effect Over 12 Months After Hospital Discharge
-0.6; -0.6

Summary

The hypothesis of this study is that using hospital admission to identify patients with poorly controlled diabetes (hemoglobin A1c levels >8%), and intervening during the hospitalization with targeted inpatient diabetes management will improve glycemic control at 3 and 12 months, with inpatient glycemic control, quality of life, and diabetes self-efficacy serving as secondary endpoints.

Eligibility Criteria

Inclusion Criteria

  • Age > 18 years
  • Known diagnosis of type 2 diabetes by history with outpatient prescription of oral hypoglycemic medication or insulin
  • Hemoglobin A1c > 8.0% within the prior 12 months, or if not known, fasting blood glucose greater than 200 mg/dl on sliding scale regular insulin.
  • Partners-affiliated primary care physician

Exclusion Criteria

  • Screening HbA1c returns less than 8%.
  • Diabetic ketoacidosis (DKA) as a primary reason for admission (admission blood glucose > 250 mg/dl with arterial pH 400 mg/dl and plasma osmolality > 315 mOsm/kg.
  • Pregnancy, ruled out by urine HCG test at screening after consent is obtained in all women who continue to have menstrual cycles.
  • Anemia with hemoglobin 15 seconds and albumin <3 mg/dl
  • End stage renal disease: Stage IV (glomerular filtration rate <30 mg/dl) or V chronic kidney disease
  • Treatment with corticosteroids
  • ICU transfer
  • Inability to self-administer insulin
  • Hypoglycemia unawareness: patient lacks sensation of common signs of blood glucose < 60 mg/dl (tachycardia, diaphoresis, hunger, confusion, fatigue).
  • Projected survival < 1 year
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00869362). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search